{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T07:07:40Z","timestamp":1773644860132,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1016\/j.clinthera.2006.10.019","type":"journal-article","created":{"date-parts":[[2006,12,6]],"date-time":"2006-12-06T12:11:17Z","timestamp":1165407077000},"page":"1670-1676","source":"Crossref","is-referenced-by-count":17,"title":["Allele variants of the cytochrome P450 2C9 genotype in white subjects from the netherlands with serious gastroduodenal ulcers attributable to the use of NSAIDs"],"prefix":"10.1016","volume":"28","author":[{"given":"Harald E.","family":"Vonkeman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mart A.F.J.","family":"van de Laar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Job","family":"van der Palen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacobus R.B.J.","family":"Brouwers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Istvan","family":"Vermes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2006.10.019_bib1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00045391-200007020-00008","article-title":"Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: A view from the ARAMIS database. Arthritis, Rheumatism, and Aging Medical Information System","volume":"7","author":"Singh","year":"2000","journal-title":"Am J Ther"},{"key":"10.1016\/j.clinthera.2006.10.019_bib2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00001574-199911000-00004","article-title":"Nonsteroidal anti-inflammatory drug gastrointestinal toxicity","volume":"15","author":"Cryer","year":"1999","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.clinthera.2006.10.019_bib3","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1136\/gut.28.5.527","article-title":"Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration","volume":"28","author":"Armstrong","year":"1987","journal-title":"Gut"},{"key":"10.1016\/j.clinthera.2006.10.019_bib4","series-title":"Poster presented at: American College of Rheumatology Annual Scientific Meeting","article-title":"Costs of hospitalization and treatment of gastrointestinal ulcers attributable to nonsteroidal anti-inflammatory drugs in The Netherlands","author":"Vonkeman","year":"1793"},{"key":"10.1016\/j.clinthera.2006.10.019_bib5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0002-9343(91)90118-H","article-title":"Nonsteroidal anti-inflammatory drug-associated gastropathy: Incidence and risk factor models","volume":"91","author":"Fries","year":"1991","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2006.10.019_bib6","first-page":"18","article-title":"Epidemiology of NSAID induced gastrointestinal complications","volume":"56","author":"Singh","year":"1999","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.clinthera.2006.10.019_bib7","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis","volume":"343","author":"Bombardier","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2006.10.019_bib8","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2006.10.019_bib9","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/00001648-200109000-00018","article-title":"Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs","volume":"12","author":"Garcia Rodriguez","year":"2001","journal-title":"Epidemiology"},{"key":"10.1016\/j.clinthera.2006.10.019_bib10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1046\/j.0306-5251.2001.01220.x","article-title":"Upper gastrointestinal bleeding among users of NSAIDs: A populationbased cohort study in Denmark","volume":"53","author":"Mellemkjaer","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2006.10.019_bib11","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/archinte.163.1.59","article-title":"Use of selective serotonin reuptake inhibitors and risk of gastrointesti-nal tract bleeding: A population-based cohort study","volume":"163","author":"Dalton","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2006.10.019_bib12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1136\/gut.46.1.27","article-title":"Peptic ulcer bleeding: Accessory risk factors and interactions with nonsteroidal anti-inflammatory drugs","volume":"46","author":"WeiI","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.clinthera.2006.10.019_bib13","first-page":"265","article-title":"Polymorphisms in drugmetabolizing enzymes: What is their clinical relevance and why do they exist?","volume":"60","author":"Nebert","year":"1997","journal-title":"Am j Hum Genet"},{"key":"10.1016\/j.clinthera.2006.10.019_bib14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1081\/DMR-120001392","article-title":"Summary of information on human CYP enzymes: Human P450 metabolism data","volume":"34","author":"Rendic","year":"2002","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.clinthera.2006.10.019_bib15","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/00008571-199610000-00007","article-title":"Genetic analysis of the human cytochrome P450 CYP2C9 locus","volume":"6","author":"Stubbins","year":"1996","journal-title":"Pharmacogenetic"},{"key":"10.1016\/j.clinthera.2006.10.019_bib16","year":"2004","journal-title":"GeneSNPs Public Internet Resource, CYP2C9"},{"key":"10.1016\/j.clinthera.2006.10.019_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clpt.2004.08.009","article-title":"Clinical consequences of cytochrome P450 2C9 polymorphisms","volume":"77","author":"Kirchheiner","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2006.10.019_bib18","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00008571-200204000-00010","article-title":"Cytochrome P450 2C9 Polymorphisms: Acomprehensive reviewofthe in-vitro and human data","volume":"12","author":"Lee","year":"2002","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.clinthera.2006.10.019_bib19","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S0169-409X(02)00076-5","article-title":"CYP2C9 allelic variants: Ethnic distribution and functional significance","volume":"54","author":"Xie","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.clinthera.2006.10.019_bib20","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/00008571-200112000-00008","article-title":"Identification of a null allele of CYP2C9 in an African American exhib iting toxicity to phenytoin","volume":"11","author":"Kidd","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.clinthera.2006.10.019_bib21","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1046\/j.0306-5251.2001.01460.x","article-title":"Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and black African population","volume":"52","author":"Scordo","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2006.10.019_bib22","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/00008571-199710000-00011","article-title":"Genetic analysis of CYP2C9 polymorphism in a Japanese population","volume":"7","author":"Nasu","year":"1997","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.clinthera.2006.10.019_bib23","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00008571-200308000-00005","article-title":"Influence of CYP2C9 genetic polymorphisms on pharmacokinet ics of celecoxib and its metabolites","volume":"13","author":"Kirchheiner","year":"2003","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.clinthera.2006.10.019_bib24","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3940(99)00278-5","article-title":"Neurogenetic correlates of Parkinson's disease: Apolipoprotein-E and cytochrome P450 2D6 genetic polymorphism","volume":"266","author":"Bon","year":"1999","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.clinthera.2006.10.019_bib25","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1124\/dmd.105.006452","article-title":"Impact of CYP2C9 genotype on pharmacogenetics: Are all cyclooxygenase inhibitors the same?","volume":"33","author":"Rodrigues","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2006.10.019_bib26","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1046\/j.0306-5251.2001.01398.x","article-title":"Is cytochrome P450 2C9 genotype associated with NSAI D gastric ulceration?","volume":"51","author":"Martin","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2006.10.019_bib27","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/sj.bjp.0705623","article-title":"Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use","volume":"141","author":"Martinez","year":"2004","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clinthera.2006.10.019_bib28","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1345\/aph.1C157","article-title":"Concomitant coumarinNSAID therapy and risk for bleeding","volume":"37","author":"Knijff-Dutmer","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2006.10.019_bib29","first-page":"1185","article-title":"Pharmacogenetics of acenocoumarol: Cytochrome P450 CYP2C9 Poly morphisms influence dose requirements and stability of anticoagulation","volume":"87","author":"Tassies","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.clinthera.2006.10.019_bib30","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/00008571-200011000-00010","article-title":"The possession of the CYP2C9*3 allele is associated with low dose requirement of acenocoumarol","volume":"10","author":"Thijssen","year":"2000","journal-title":"Pharma cogenetics"},{"key":"10.1016\/j.clinthera.2006.10.019_bib31","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1160\/TH03-05-0325","article-title":"Potential interaction between acenocoumarol and diclofenac, naproxen and ibuprofen and the role of CYP2C9 genotype","volume":"91","author":"van Dijk","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinthera.2006.10.019_bib32","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.clpt.2005.02.009","article-title":"Allelic variants of cytochrome P450 2C9 modify the interaction be tween nonsteroidal anti-inflammatory drugs and coumarin anticoagulants","volume":"77","author":"Visser","year":"2005","journal-title":"Clin Pharmacol Ther"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806002591?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806002591?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,22]],"date-time":"2019-04-22T18:53:44Z","timestamp":1555959224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291806002591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["S0149291806002591"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2006.10.019","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}